Abstract
Introduction
Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by a multiplicity of symptoms and signs, and a variable impact on physical, psychological and social functioning. Health-related quality of life (HRQOL) and other patient-reported outcomes (PROs) are key for assessing the disease from the patient's perspective. [1] [2] [3] However, it is recommended that PRO questionnaires should be as brief as possible in order to minimize respondent burden. 4, 5 For MS patients in particular, presence of fatigue and impairment of sustained attention are common symptoms, which can limit patient's ability to complete long PRO instruments. 6 Since 1995, a number of MS-specific HRQOL instruments have been produced. [6] [7] [8] [9] With 51 translations available (https://eprovide.mapi-trust.org/instruments/multiple-sclerosis-quality-of-life-54), the 54-item MS Quality of Life inventory (MSQOL-54) is one of the most-used MS-specific questionnaires. 2, 10 In a previous study phase, we shortened the MSQOL-54 using a combination of psychometric analyses (factor analysis and Rasch modelling) applied on a dataset of 635 MS patients, who completed the MSQOL-54, and input from MS/HRQOL professionals and MS patients. 11 The resulting MSQOL-29 consists of seven multi-item and four single-item subscales, used to form two composite scores, consistent with the theoretical construct used to develop the original instrument. 12 MSQOL-29 requires approximately 10 minutes to complete, corresponding to half of the MSQOL-54 completion time. 13 Nonetheless, the high correlation of MSQOL-29 subscale and composite scores with those of MSQOL-54 suggests that eliminating items and subscales did not substantially change the HRQOL dimensions found for the original instrument. The electronic version provides an alternative administration mode, and can be integrated within electronic health records and disease registries. Another advantage of the electronic mode of administration is the score calculation routine which, by reducing computational burden and errors, should facilitate the use of HRQOL measures in clinical practice, and ultimately the patient-provider communication and shared decision-making. However, to have confidence in the validity of data collected using different administration modes, and to allow pooled analyses when different versions are used within and between studies, between-mode equivalence and acceptability must be formally evaluated. [14] [15] [16] Here are presented the results of a prospective study aimed to assess MSQOL-29 acceptability, validity and reliability, and to confirm its factorial structure in an independent population. In addition, we assessed the equivalence of the electronic version to the paper version.
Methods

Participants
We used a cross-sectional design, with consecutive sampling, and a nested longitudinal equivalence study. Participants were included with a clinical diagnosis of MS 17 and were at least 18 years of age, able to read and understand Italian, and to provide written informed consent. Recruitment occurred at five centres across Italy (Foundation IRCCS Neurological Institute C. Besta, Milan; University Hospital San Luigi Gonzaga, Orbassano, Turin; IRCCS S. Lucia Foundation, Rome; G. d'Annunzio University of Chieti-Pescara, Chieti; and University Hospital Policlinico Vittorio Emanuele, Catania). The study was approved by the ethics committee of the five participating centres.
PRO measures
MSQOL-29 consists of seven multi-item subscales: 'physical function' (six items); 'sexual function' (four items); 'bodily pain', 'emotional well-being', 'energy', 'cognitive function' and 'health distress' (three items); and four single-item subscales ('social function', 'health perceptions', 'overall quality of life', and 'change in health') which form two composite scores (Physical Health Composite, (PHC) and Mental Health Composite, (MHC)). 11 A filter question (During the past 4 weeks, have you had an active sexual life?) is present after the first 'sexual function' item (How much of a problem was lack of sexual interest for you during the past 4 weeks?). If the reply is 'no', the other three 'sexual function' items are not shown (eMSQOL-29) or are skipped (paper format). An integrated scoring routine is available for eMSQOL-29, to ease score calculation and interpretation.
The Functional Assessment of MS (FAMS) consists of a generic core HRQOL measure (the Functional Assessment of Cancer Therapy-General scale), supplemented with MS-specific items. 18 The 59 items of the FAMS are divided into 6 subscales: 'mobility', 'symptoms', 'emotional well-being', 'general contentment', 'thinking/fatigue' and 'family/social wellbeing'. Only items 1-44 are included in the total score (0-4 score range for each), which can range from 0 to 176 (best HRQOL).
The European Quality of life Five Dimensions-3L (EQ-5D-3L) is a standardized instrument providing a generic measure of health, via a descriptive system addressing five health state dimensions ('mobility', 'self-care', 'usual activities', 'pain/discomfort' and 'anxiety/depression'), each scored on a three-level scale. A visual analogue scale (VAS) is also included to measure overall health. By combining every characteristic level of the descriptive system, a total of 243 profiles can be obtained, within the range 11,111-33,333 (worst health state). The profiles can be assigned an index score (utility value, available for several countries included Italy), which represents preferences for that profile derived from a general population survey. 19, 20 The index has a maximum value of 1 (full health), an anchor of 0 for a state equivalent to being dead and values <0 for states regarded as worse than being dead.
The Hospital Anxiety Depression Scale (HADS) is a screening tool comprising 14 multiple-choice items (0-3 score range for each), 7 probing symptoms of anxiety and 7 of depression. HADS anxiety and depression scores are obtained, which can range from 0 to 21 (most severe symptoms). 21 Procedure All participants signed the informed consent form, then completed the eMSQOL-29, 11 a section on questionnaire acceptability (see below), and (in citation order), Italian versions of the following inventories: the HADS, 22 FAMS, 23 and EQ-5D-3L. All the questionnaires were completed by the patients on the personal computer (PC). The MS clinician administered the Expanded Disability Status Scale (EDSS), 24 the Symbol Digit Modalities Test (SDMT), 25 and recorded patient general and clinical information. eMSQOL-29 acceptability and usability were assessed by rating (0-10 VAS) the suitability of the MSQOL-29 as an MS-specific QOL inventory; and the following four characteristics: being taxing, boring, difficult to read and difficult to complete. Each characteristic was rated on a 0-3 scale, followed by a multiple-choice question exploring the main reasons for difficulty.
A minimum of 200 participants from Milan and Orbassano centres completed both paper and eMSQOL-29 in random order, and in 2-week intervals. Retest was performed at the patients' homes (except for patients preferring to complete at the MS centre). At the end of the visit, participants assigned to the electronic-paper order were given a closed envelope, to be opened after 2 weeks, containing the MSQOL-29 questionnaire and a pre-addressed, return-paid envelope. A few days before retest date, participants assigned to the paper-electronic order received an email with the link to the website containing the eMSQOL-29.
After retesting, eMSQOL-29 acceptability was assessed as reported above; in addition one multiplechoice item assessed the preferred version (electronic, paper, no preference).
One week after the expected completion/return date, patients who did not complete/return the questionnaire received a reminder (email or phone call).
Statistical analysis
Internal reliability was assessed using Cronbach's alpha (benchmark value >0.70). For each MSQOL-29 subscale, we determined the presence of floor effect (>10% of the patients scoring the minimum) and ceiling effect (>10% of the patients scoring the maximum). Criterion validity was assessed as follows: concurrent validity was evaluated by correlating MSQOL-29 subscale scores and pertinent subscale/scale scores of FAMS, EQ-5D-3L and HADS (Pearson's r); predictive validity was assessed using the EDSS (two groups, cutoff point 4.5). For the latter, independent sample t-test and Cohen's d were used. A d of 0.50 corresponds to a moderate effect size and a d of 0.80 to a large effect size.
We conducted a confirmatory factor analysis (CFA) to test the two-factor structure proposed by Vickrey et al. 10 for MSQOL-54, using the following cutoff criteria for the goodness-of-fit indices: root mean square error of approximation (RMSEA) <0.05, comparative fit index (CFI) <0.95 and standardized root mean square residual (SRMR) ≤0.08.
For each of the 11 MSQOL-29 subscale scores, equivalence of paper and electronic version was assessed using a randomized cross-over design, which allows for testing of version (paper, electronic), order (test, retest), effects and their interactions (sequence). The required sample size (185 patients) was calculated under the following assumptions: intra-class correlation coefficient (ICC) 26 between versions of 0.80 (vs a reference value of 0.70), 80% power for detecting this difference, 5% alpha error, two-tailed test and 20% missing items plus drop-outs. 27 In addition to the ICC, we assessed the effect size statistic (benchmark value ≤0.20) 28 and linear regression model for repeated measures design, with an exchangeable correlation structure of the errors. The model included the following independent variables: MSQOL-29 version, order, sequence, centre (Milan, Orbassano), sex, age, EDSS (≤2.5, >2.5) and disease course (relapsing-remitting, primary or secondary progressive).
All the analyses were performed with SAS version 9.4 and LISREL version 8.72. Significance level was set at 0.05.
Results
Participants' characteristics
Between September 2015 and May 2016, 623 adult MS patients were assessed (Table 1) . Of these, 424 (68%) were women and the mean age was 44 years (range 20-78). Most had relapsing-remitting MS (82%) and median EDSS score was 2.5 (range 0.0-9.0). General and clinical characteristics of the patients were similar across the centres, except for a lower proportion of relapsing-remitting MS (53%) and a higher EDSS score (median 6.0) in Rome (Table 1) , reflecting the case-mix of a rehabilitation centre. A total of 41 patients (7%) were excluded from the analyses because of incomplete data. A total of 233 MS patients (Milan n = 92, Orbassano n = 141) participated in the longitudinal equivalence study. 
Psychometric properties of eMSQOL-29
Missing replies for eMSQOL-29 ranged from 0.2% to 5.7% (item 29), and three of the four 'sexual function' items were filtered out by 273 patients (47%). After confirmation of the invariance of the instrument in the two subsamples (Online Supplementary Appendix A), the 'sexual function' subscale score was computed using all the available information (i.e. one item or four items, depending on the response to the filter question). As expected, respondents who skipped the sexual items were on average older and with a more severe disease (Table 2 ).
There was no floor effect for any multi-item scale, while a ceiling effect was present for 'physical function', 'sexual function', 'cognitive function', 'bodily pain' and 'health distress'. Cronbach's alpha ranged from 0.88 to 0.90 ( (Table 4) .
Correlations between eMSQOL-29 and FAMS subscales addressing similar domains ranged from 0.62 to 0.86, except for 'social function' (0.38; p < 0.001).
Correlation between 'emotional well-being' and HADS subscales was −0.59 for anxiety (p < 0.0001) and −0.56 for depression (p < 0.0001). Correlation between 'cognitive function' and SDMT was poor (0.25; p < 0.0001). Finally, 'overall quality of life' correlated highly with the EQ-5D VAS (0.66; p < 0.0001), than with the EQ-5D-3L index (0.48; p < 0.0001; Table 5 ).
The radar plot of MSQOL-29 subscale/composite scores by EDSS score (Figure 1 ) shows large effect sizes (Cohen's d > 0.80) for 'physical function', 'overall quality of life', 'energy', 'social function' and both composite scales. 
eMSQOL-29 acceptability
The overall mean rating of the eMSQOL-29 acceptability was 6.9 standard deviation (SD) 1.8), with about 75% of patients (N = 426/564) considering it as suitable (VAS score ≥6). There were no significant differences in the evaluation according to the patient clinical and demographic characteristics (i.e. age, education, EDSS and centre; Online Supplementary Figure) . Of 581 patients, 16 (2.8%) considered the questionnaire as being taxing, 33/579 (5.7%) as boring. None of the patients found the questionnaire difficult to read or complete.
Equivalence study
Of the 233 MS patients enrolled, 220 (94%) completed both the questionnaire versions and 13 did not return the paper MSQOL-29. Missing replies for the paper version ranged from 1 (0.5%) to 5 (2%, item 1); for eMSQOL-29, it was from 1 (0.45%) to 12 (5%, item 29).
Eight of the 11 subscales had ICC values ≥0.70 (Table  6) Table 6 ). (Table 7) . Finally, 87 (40%) did not express any preference about the version, 2 missed the answer, while the remaining 131 were equally divided between those who preferred the paper (n = 65) and eMSQOL-29 (n = 66).
Discussion
We recently devised an abbreviated version of MSQOL-54, also available in electronic version (eMSQOL-29), using a combination of factor analysis and Rasch modelling. The conceptualization of MSQOL-29 is similar to the parent HRQOL scales, MSQOL-54 10 and SF-36: 29 'physical function', 'cognitive function', 'sexual function' and 'social function' subscales aim to capture the behavioural consequences of the health problem (here MS); 'emotional well-being', 'bodily pain', 'energy', 'health distress', 'health perceptions' and 'change in health' aim to reflect more subjective components of health;
and 'overall quality of life' intends to capture overall satisfaction with life and well-being. 30 In this study we confirmed eMSQOL-29 reliability, validity and factorial structure in a prospective, independent MS patient sample. In addition, we demonstrated eMSQOL-29 acceptability, and equivalence with the paper version.
An unexpected finding was the high proportion of patients (47%) who filtered out the 'sexual function' items, which outnumbered missing items of the parental questionnaire, where the filter question is not present. 11 Acknowledging the worth of addressing sexuality in MS, 10, 31, 32 exploring sexual functioning over a 4-week period can be challenging, especially for older and more disabled patients (Table 2) . In these patients, using a single item (item 24) can be worthwhile. Importantly, by demonstrating the measurement invariance of the 'sexual function' subscale score obtained from item 24 versus the full set of items (items 24-27), we supported the use of this scale in the proposed adaptive version. However, an MS-specific instrument, such as the Multiple Sclerosis Intimacy and Sexuality Questionnaire-15 can be added to eMSQOL-29 to explore in more detail sexual functioning 33 in MS patients.
Concerning missing items, the last eMSQOL-29 item (item 29, 'overall quality of life') had 5% of missing replies (vs no missing replies in the paper version). Item 29 is the only item in which response is obtained by moving the mouse along a VAS, which can be demanding to patients with tremor or impaired arm function.
Concurrent validity, assessed using various instruments, was acceptable, the only two exceptions being the sub-optimal correlations between 'social function' and FAMS 'family/social well-being', and between 'cognitive function' and SDMT. Concerning the social function domain, this can originate from differences in item contents between the questionnaires: MSQOL-29 'social function' referring to social activities with family, friends and social relations; by contrast, FAMS 'family/social well-being' focuses on social activities within the family. To better appraise the reason for the low correlation between MSQOL-29 'cognitive function' and SDMT (r = 0.25; p < 0.0001), we assessed the correlation between FAMS 'thinking/fatigue' and SDMT, which was also low (r = 0.24; p < 0.0001). This finding indicates that the most used screening measure of MS cognitive compromise little correlated with patient self-perceived impact of cognitive problems on daily functioning. Poor correlations between subjective and objective measures of cognitive impairment have also been reported elsewhere. 34, 35 As expected, the EDSS well differentiated several MSQOL-29 subscale scores (chiefly the 'physical function'; Figure 1 ).
The equivalence between eMSQOL-29 and the paper version was good, with ICC values >0.70 in 8 of the 11 subscales, and negligible effect sizes, supporting comparison and pooled analysis of data obtained from the two modes of administration. 36 
Study limitations
Power calculation was made only for the equivalence study. However, the size of our clinical validation sample was quite large, and the sample well varied in terms of disease severity, duration and socio-demographic characteristics.
Another limitation is that usability and pilot testing were not meticulous enough. Thanks to the study findings, refinements will be made to eMSQOL-29 to improve its usability by patients with impaired arm function. Specifically, a picker wheel widget will be used to rate the VAS; after rating, an automated feedback message will appear, reporting the selected VAS score; and an alerting message (in case of missing rating) to prevent inadvertent missing replies. These refinements are minor modifications that do not alter the content, meaning or interpretation at the item or scale level, and will not require any formal validation besides cognitive debriefing and usability testing. 14, 15 To conclude, eMSQOL-29 (with integrated scoring routine) has good psychometric properties and is equivalent to the paper version. The good level of agreement between the electronic and paper versions should be reassuring to investigators, authorities and sponsors using electronic devices to collect PRO data, having implications for the use of electronic measures. 15 Both versions can be easily used at the international level in clinical practice and research. Work needs to be carried out within a longitudinal design to assess the instrument's responsiveness-the ability to detect change over time in the construct to be measured, 37 and response shift-where the meaning of scores changes over time as patients adapt to their illness. 38 For this reason, it is premature to recommend use of eMSQOL-29 as an outcome measure in clinical trials. However, its conceptual and methodological strengths, combined with the good psychometric properties here described suggest that eMSQOL-29 may have a place among the MS-specific HRQOL instruments. Further, questionnaire brevity limits compilation burden, real-time scoring prevents scoring burden and errors, and supports use during the consultation to promote shared decision-making and patient-centred care. 39 
